Abgenix Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Fremont CA United States (1996)
Status: Acquired by Amgen (2005)

Organization Overview

First Clinical Trial
1999
NCT00035880
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

gavilimomab (1 trial)

Drugs in Phase 2 Trials (2)

abx-il8 (1 trial)

panitumumab (vectibix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 2)

Bronchitis (Phase 2)

Bronchitis, Chronic (Phase 2)

Graft vs Host Disease (Phase 3)

Lung Diseases (Phase 2)

Prostatic Neoplasms (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3